Clinical Trial Update: Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and tolerability of pegylated interferon alfa-2a in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED